Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a ...

Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

Europe's pharma sector now trails the US, it went on to say, "on every investor metric from availability of capital, intellectual property, speed of approval to rewards for innovation", and even ...

'Want to show a different face' - Kovac on Dortmund playing better in Barca 2nd leg Tutankhamun and his gold-laden tomb have ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Moreover, some of Pfizer’s products may face patent expirations soon, which may impact the company. Hence, those willing to buy shares of Pfizer must wait patiently for further catalysts ...

Pfizer does face several risks that investors should weigh carefully. For instance, competition is increasing for two key products. Prevnar, Pfizer's blockbuster pneumococcal vaccine, faces ...

Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a ...